Validation of a Rapid and Sensitive HPLC-UV Method for the Quantification of Eprosartan Mesylate in Bulk Drug, TeventenTM and Ultradeformable Lipid Based Vesicular System

Title:Validation of a Rapid and Sensitive HPLC-UV Method for the Quantification of Eprosartan Mesylate in Bulk Drug, TeventenTM and Ultradeformable Lipid Based Vesicular System

Volume: 12 Issue: 3

Author(s): Abdul Ahad, Abdullah Mohammed Al-Mohizea, Abdulmohsen Abdullah Al-Saleh, Abdullah Sulaman Alwabel, Abdulaziz Jaber Aqel, Khalid Mahdi Al-Qahtani and Fahad Ibrahim Al-Jenoobi

Affiliation:

Keywords: Eprosartan mesylate, HPLC-UV, teventen, ultradeformable lipid based formulation.

Abstract: Background: Methods reported so far in literature, considered to be less sensitive, uneconomical and time consuming; overall run time more than 10 minutes.

Objective: From economic point of view and for the purpose of routine analysis, it was decided to develop a simple, more sensitive, rapid and economical HPLC method for estimation of EM.

Method: A HPLC analytical method has been developed for the quantification of eprosartan in bulk drugs and pharmaceutical formulations at 235 nm using HPLC-UV detector. Chromatographic separation was performed on a Waters^® C₁₈ column (µBondapak^TM5 µm, 150 mm x 3.9 mm i.d). The acetonitrile and potassium dihydrogen orthophosphate buffer (20mM, pH 3) in ratio of 35%: 65% respectively was used as mobile phase; which pumped at a flow rate of 1.2 ml/min. The developed analytical method was validated following ICH guidelines taking linearity, accuracy, precision, sensitivity, selectivity, robustness and stability of method into consideration.

Result: The calibration curves were found linear with regression coefficient (r²) of 0.99. The developed method was found to be rapid and sensitive; as the retention time for eprosartan was found to be lesser than 5 min and the LOD and LOQ were found to be 0.014 µg/ml and 0.042 µg/ml, respectively. Additionally, the developed method was successfully applied for the estimation of eprosartan in pharmaceutical formulations (bulk drug, tablet and ultradeformable lipid based formulation).

Conclusion: The developed method was found simple, rapid, accurate, and reproducible for the determination of eprosartan in bulk, tablet and in lipid based formulation.

Cite this article as:

Ahad Abdul, Mohammed Al-Mohizea Abdullah, Abdullah Al-Saleh Abdulmohsen, Sulaman Alwabel Abdullah, Jaber Aqel Abdulaziz, Mahdi Al-Qahtani Khalid and Ibrahim Al-Jenoobi Fahad, Validation of a Rapid and Sensitive HPLC-UV Method for the Quantification of Eprosartan Mesylate in Bulk Drug, TeventenTM and Ultradeformable Lipid Based Vesicular System, Current Pharmaceutical Analysis 2016; 12 (3) . https://dx.doi.org/10.2174/1573412911666150917195649